New pill may help myeloma patients stay in remission longer after transplant

NCT ID NCT05177536

Ongoing Disease control Sponsor: University of Nebraska Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called iberdomide as maintenance therapy for people with multiple myeloma who have had a stem cell transplant. The goal is to see if more patients can stay on treatment for at least a year without the disease getting worse. About 40 adults will take iberdomide pills for 21 days each month, and researchers will monitor how well they tolerate it and how long they remain cancer-free.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iberdomide (a pill that helps the immune system attack cancer cells)
What this could lead to: If successful, this could offer a better-tolerated maintenance option for multiple myeloma patients after stem cell transplant, potentially reducing relapse.
What could go wrong: This is a small, early-phase study with only 40 participants. It may not show clear benefit, and iberdomide could still cause side effects or fail to prevent relapse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.